Technology
The company's drug discovery platform, Quantum Molecular Design ("QMD"), deploys an integrated combination of Artificial Intelligence, advanced quantum chemistry, and cloud computing to rapidly generate high quality drug-like hits and leads for a wide range of drug targets, including demonstrated success on targets previously considered to be "undruggable", at low cost.
The Artificial Intelligence methods used include augmented intelligence, heuristic search, expert systems and machine learning to reduce computational cost and reduce toxic side effects. The company has achieved biological activity and promising preclinical data on 100% of the drug targets it has tested so far, including allosteric targets, protein-protein interaction disruption, nuclear receptors, and drug candidates designed for selectivity.
Download our white paper:
Accurate In Silico Prediction of Ligand Binding Potency in Therapeutic Targets using Quantum Molecular Design >
Read the cover story:
CLOUD COMPUTING - Using Quantum Molecular Design & Cloud Computing to Improve the Accuracy & Success Probability of Drug Discovery >
Drug Development & Discovery
March 2016
The Artificial Intelligence methods used include augmented intelligence, heuristic search, expert systems and machine learning to reduce computational cost and reduce toxic side effects. The company has achieved biological activity and promising preclinical data on 100% of the drug targets it has tested so far, including allosteric targets, protein-protein interaction disruption, nuclear receptors, and drug candidates designed for selectivity.
Download our white paper:
Accurate In Silico Prediction of Ligand Binding Potency in Therapeutic Targets using Quantum Molecular Design >
Read the cover story:
CLOUD COMPUTING - Using Quantum Molecular Design & Cloud Computing to Improve the Accuracy & Success Probability of Drug Discovery >
Drug Development & Discovery
March 2016